Outlook Therapeutics (Outlook Therapeutics) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Outlook Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-13.03 Mil. Outlook Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Outlook Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Outlook Therapeutics's current FCF Yield % is -23.98%.

The historical rank and industry rank for Outlook Therapeutics's FCF Margin % or its related term are showing as below:

During the past 10 years, the highest FCF Margin % of Outlook Therapeutics was -103.71%. The lowest was -1563.12%. And the median was -554.78%.

OTLK's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.935
* Ranked among companies with meaningful FCF Margin % only.

Outlook Therapeutics FCF Margin % Historical Data

The historical data trend for Outlook Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics FCF Margin % Chart

Outlook Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Margin %

Get a 7-Day Free Trial

-401.76

Outlook Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Outlook Therapeutics's FCF Margin %

For the Biotechnology subindustry, Outlook Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's FCF Margin % falls into.

Outlook Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Outlook Therapeutics's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-42.973	/	0
	=	%

Outlook Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-13.032	/	0
	=	%

Outlook Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (Outlook Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

41ON:Germany 41ON:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Executives

Terry Dagnon	officer: Chief Operating Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Jeff Evanson	officer: Chief Commercial Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin	director	ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Faisal Ghiath Sukhtian	director	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger	director	1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii	director, officer: CEO and President	1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian	director, 10 percent owner	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Lawrence A Kenyon	officer: CFO and Secretary	C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Syntone Ventures Llc	10 percent owner	1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang	director	C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth	director	C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments	director	C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007